## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `ss-31-plantar-fasciitis`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/ss-31-plantar-fasciitis/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-plantar-fasciitis/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ss-31-plantar-fasciitis/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/ss-31-plantar-fasciitis/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ss-31-plantar-fasciitis/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/ss-31-plantar-fasciitis/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `ss-31-plantar-fasciitis` v2 · content_hash `7f3f2de0ce8a5034…` · thread_head genesis · 25 DIVs
- **thesis (c1):** Degenerative tenocytes from human tendon show increased mitochondrial depolarization that decreases after SS-31 treatment in cell culture.
  - c3 [human/active] No human clinical trials of SS-31 have been conducted in plantar fasciitis.
  - c4 [human/active] SS-31 received FDA approval for Barth syndrome in 2025 based on extension-phase functional improvements.
  - c2 [preclinical/active] SS-31 improved mitochondrial morphology, superoxide dismutase activity, and reduced MMP-1 and FABP4 gene expression in degenerative tenocytes.
  - c5 [anecdotal/active] No Reddit or X anecdotes mention SS-31 for plantar fasciitis.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/ss-31-plantar-fasciitis/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/ss-31-plantar-fasciitis/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `ss-31-plantar-fasciitis`
- **title:** SS-31 (Elamipretide) for Plantar Fasciitis: Mitochondrial Evidence Review
- **url:** https://miscsubjects.com/a/ss-31-plantar-fasciitis
- **register:** source_ledger
- **updated:** 2026-07-17T02:42:07.015Z
- **tags:** peptide, matrix

## Body

## What's breaking down if you have Plantar Fasciitis

Plantar fasciitis involves degenerative changes in the plantar fascia, the thick band of tissue connecting your heel bone to your toes. The tissue shows collagen disorganization, increased cell death in tenocyte-like cells, and reduced ability to handle mechanical stress from walking or standing.

If your fascia cells have mitochondrial dysfunction, energy production drops and repair slows. This creates a gap where breakdown outruns regeneration. Mitochondrial membrane potential falls, reactive oxygen species handling weakens, and genes linked to matrix breakdown rise. These layers matter because plantar fascia is under constant load; poor cellular energy makes recovery harder.

No direct human data links plantar fasciitis to SS-31. The closest evidence comes from degenerative tendon cells, which share features with fascia degeneration.

## Why SS-31 (Elamipretide) might help you

1. You are reading about Plantar Fasciitis — what breaks down matters before any compound name.
2. Therefore for you: If mitochondrial dysfunction in fascia cells is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.

SS-31 concentrates in the inner mitochondrial membrane and stabilizes cardiolipin. In degenerative tenocytes from human tendon biopsies, treatment reduced the fraction of cells with depolarized mitochondria and improved mitochondrial number and size seen on electron microscopy. Superoxide dismutase activity rose after treatment. Matrix metalloproteinase-1 expression fell, and fatty acid-binding protein 4 expression dropped. Cell viability showed small improvement.

If your plantar fascia cells behave like those degenerative tenocytes, SS-31 could support mitochondrial structure and function. That might allow better ATP production for collagen maintenance and reduce signals that promote further breakdown. The study used cultured cells from patients with rotator cuff issues, not foot fascia, so direct translation remains untested.

SS-31 does not act as a pain suppressor or anti-inflammatory drug in the classic sense. It addresses cellular energy deficits that may underlie poor tissue repair in degenerative conditions.

## How these fit together

Single-compound focus — SS-31 (Elamipretide) targets the mitochondrial layer. If your condition profile includes other degeneration layers such as mechanical overload or inflammation, those would require separate approaches. SS-31 addresses energy production inside cells so repair pathways have a better chance to keep pace with daily loading on the fascia.

## What the evidence actually shows

The key study is an in vitro model using tenocytes from human degenerative supraspinatus tendons versus healthy hamstring tendons (Zhang et al., 2022, Am J Sports Med). Researchers cultured cells at passage 1 and exposed degenerative cells to 1 μM SS-31 for 72 hours. They measured mitochondrial depolarization, morphology via transmission electron microscopy, antioxidant enzyme activity, gene expression, and cell viability.

Findings: degenerative tenocytes had more depolarized mitochondria and smaller, fewer mitochondria. SS-31 reversed these changes. Antioxidant activity improved. Remodeling and fatty infiltration genes normalized. The study is preclinical (human cells in culture) and does not prove effects in living people with plantar fasciitis.

Human trials of SS-31 exist for primary mitochondrial myopathy and Barth syndrome. One phase 2/3 trial in Barth syndrome showed functional improvements in the open-label extension but missed primary endpoints in the blinded phase. No trials test SS-31 in plantar fasciitis or any foot condition.

## What scientists say

The tendinopathy paper concludes that mitochondrial dysfunction appears in degenerative tenocytes and SS-31 may improve mitochondrial function to promote healing. Authors note clinical relevance for tendinopathy but call for further work. Broader reviews describe SS-31 as a cardiolipin stabilizer that supports electron transport and reduces oxidative stress in multiple mitochondrial disease models. No published statements address plantar fasciitis specifically.

## What people say on Reddit

No posts or threads were identified discussing SS-31 or elamipretide in the context of plantar fasciitis or foot pain. Searches returned zero relevant anecdotes.

## What people say on X

No posts were identified linking SS-31 to plantar fasciitis. General discussions of the peptide focus on Barth syndrome approval or mitochondrial myopathy trials.

## What we do not know

No human trials exist for SS-31 in plantar fasciitis. No animal models of plantar fasciitis treated with SS-31 have been published. Whether improved mitochondrial function in cultured tendon cells translates to fascia repair in vivo remains unknown. Long-term safety and functional outcomes in musculoskeletal tissues are unstudied for this indication. Weight loss can reduce compressive forces on the plantar fascia (roughly 4 lb per pound lost), but SS-31 itself has no documented effect on body weight.

## Safety and limits

SS-31 has been tested in human trials for mitochondrial myopathy and Barth syndrome with generally good tolerability reported. Common side effects in those studies were mild and included injection-site reactions. The compound received FDA approval for Barth syndrome in 2025. All other uses remain investigational. No data exist on interactions with common plantar fasciitis treatments or on long-term use in otherwise healthy individuals. This review reports published findings only and does not constitute guidance.

## Claims (5)

- **c3** [human w=0.8] No human clinical trials of SS-31 have been conducted in plantar fasciitis.
  - who_claims: grok/grok-4.3
  - sources: s2
- **c1** [preclinical w=0.5] Degenerative tenocytes from human tendon show increased mitochondrial depolarization that decreases after SS-31 treatment in cell culture.
  - who_claims: grok/grok-4.3
  - sources: s1
- **c2** [preclinical w=0.5] SS-31 improved mitochondrial morphology, superoxide dismutase activity, and reduced MMP-1 and FABP4 gene expression in degenerative tenocytes.
  - who_claims: grok/grok-4.3
  - sources: s1
- **c5** [anecdotal w=0.3] No Reddit or X anecdotes mention SS-31 for plantar fasciitis.
  - who_claims: grok/grok-4.3
- **c4** [human w=0.8] SS-31 received FDA approval for Barth syndrome in 2025 based on extension-phase functional improvements.
  - who_claims: grok/grok-4.3
  - sources: s3

## Voxel graph (5 atoms · 9 edges)
- full graph: https://miscsubjects.com/api/articles/ss-31-plantar-fasciitis/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (3)
- chain valid: yes · head: `1e32ffca2ef4addb`

### s1 · pubmed · ok
- title: Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model
- url: https://pubmed.ncbi.nlm.nih.gov/35862638/
- summary: In vitro study on human tenocytes showing SS-31 effects on mitochondria and gene expression in degenerative cells.
- quote: There are changes in mitochondrial structure and function in tenocytes derived from degenerative tendons, and SS-31, as a mitochondrial protectant, could improve mitochondrial function and promote the healing of tendinopathy.
- claim_ids: c1, c2
- hash: `f097611dea886dec`

### s2 · pubmed · ok
- title: Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model
- url: https://pubmed.ncbi.nlm.nih.gov/35862638/
- summary: Explicit statement of no prior exploration in tendinopathy, extending to plantar fasciitis.
- quote: The potential of SS-31 in treating tendinopathy has not been explored.
- claim_ids: c3
- hash: `27a377688ad1ac77`

### s3 · news · ok
- title: FDA Approval for Mitochondrial Therapeutic Elamipretide, Formerly SS-31
- url: https://www.fightaging.org/archives/2025/10/fda-approval-for-mitochondrial-therapeutic-elamipretide-formerly-ss-31/
- summary: Reports 2025 FDA approval for Barth syndrome and trial context.
- quote: The recent FDA approval of elamipretide is for the treatment of a rare disease
- claim_ids: c4
- hash: `1e32ffca2ef4addb`

## Provenance (2 model passes)
- chain valid: yes · head: `0411ce842fed4a54`

- write · grok/grok-4.3 · 2026-06-29T23:48 · hash `c78f0d4e578d`
- voxel_divide · owner · 2026-07-17T02:42 · hash `0411ce842fed`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/ss-31-plantar-fasciitis/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/ss-31-plantar-fasciitis/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"ss-31-plantar-fasciitis","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest ss-31-plantar-fasciitis|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim ss-31-plantar-fasciitis|tier|assertion`
- **iMessage ask:** `ss-31-plantar-fasciitis|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `ss-31-plantar-fasciitis`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-plantar-fasciitis/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ss-31-plantar-fasciitis/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*